Bluejay Diagnostics (NASDAQ:BJDX) Upgraded at Wall Street Zen

Posted by Brenda Bartman on Jul 21st, 2026

Wall Street Zen upgraded shares of Bluejay Diagnostics (NASDAQ:BJDX – Free Report) to a sell rating in a report published on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bluejay Diagnostics has an average rating of “Sell”.

Read Our Latest Research Report on BJDX

Bluejay Diagnostics Stock Down 16.6%

Shares of BJDX stock opened at $1.21 on Friday. The company’s fifty day simple moving average is $2.63 and its 200-day simple moving average is $2.43. The firm has a market cap of $1.25 million, a PE ratio of -0.10 and a beta of 0.88. Bluejay Diagnostics has a 12 month low of $1.03 and a 12 month high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In related news, major shareholder Financial Lp Hrt purchased 64,047 shares of the stock in a transaction on Thursday, July 9th. The shares were purchased at an average cost of $1.51 per share, with a total value of $96,710.97. Following the acquisition, the insider directly owned 126,993 shares in the company, valued at $191,759.43. The trade was a 101.75% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 6.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

(Get Free Report)

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.